Pharmacogenomics of metabotropic glutamate receptor subtype 1 and in vivo malignant melanoma formation

Journal of Dermatology

Volumn 37, Issue 7, 2010, Pages 635-646

  Abdel Daim, Mohamed ^a   Funasaka, Yoko ^a   Komoto, Mari ^a   Nakagawa, Yoko ^a   Yanagita, Emmy ^a   Nishigori, Chikako ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

melanoma; mGluR1; pharmacogenomics; signal; transgenic

Indexed keywords

CALCIUM ANTAGONIST; CALMODULIN; KI 67 ANTIGEN; METABOTROPIC RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOLIPASE C INHIBITOR; PHOSPHOLIPASE INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; STEM CELL FACTOR; METABOTROPIC GLUTAMATE RECEPTOR TYPE 1; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHOLIPASE C; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CELL PROLIFERATION; GENE ACTIVATION; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PHARMACOGENOMICS; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SKIN TUMOR;

ANIMALS; CALMODULIN; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOMA; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTORS, METABOTROPIC GLUTAMATE; SKIN NEOPLASMS; STEM CELL FACTOR; TYPE C PHOSPHOLIPASES;

EID: 77954227029     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.00833.x     Document Type: Article

References (35)

1. Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S. Sequence and expression of a metabotropic glutamate receptor. Nature 1991 349 : 760 765.
2. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992 258 : 597 603.
3. Nakanishi S. Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity. Neuron 1994 13 : 1031 1037.
4. Aiba A, Chen C, Herrup K, Rosenmund C, Stevens CF, Tonegawa S. Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell 1994 79 : 365 375.
5. Aiba A, Kano M, Chen C et al. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 1994 79 : 377 388.
6. Conquet F, Bashir ZI, Davies CH et al. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature 1994 372 : 237 243.
7. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 2001 98 : 6372 6377.
8. Stepulak A, Sifringer M, Rzeski W et al. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 2005 102 : 15605 15610.
9. Pollock PM, Cohen-Solal K, Sood R et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003 34 : 108 112.
10. Marin YE, Namkoong J, Shin SS et al. Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes. Neuropharmacology 2005 49 (Suppl 1 70 79.
11. Namkoong J, Shin SS, Lee HJ et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007 67 : 2298 2305.
12. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997 37 : 205 237.
13. Karim F, Wang CC, Gereau RWt. Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. J Neurosci 2001 21 : 3771 3779.
14. Thandi S, Blank JL, Challiss RA. Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways. J Neurochem 2002 83 : 1139 1153.
15. Marin YE, Namkoong J, Cohen-Solal K et al. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signal 2006 18 : 1279 1286.
16. Ohtani Y, Harada T, Funasaka Y et al. Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 2008 27 : 7162 7170.
17. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992 89 : 5547 5551.
18. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 2002 108 : 135 144.
19. Kunisada T, Lu SZ, Yoshida H et al. Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med 1998 187 : 1565 1573.
20. Chen J, Kelz MB, Zeng G et al. Transgenic animals with inducible, targeted gene expression in brain. Mol Pharmacol 1998 54 : 495 503.
21. Estella-Hermoso de Mendoza A, Campanero MA, de la Iglesia-Vicente J, Gajate C, Mollinedo F, Blanco-Prieto MJ. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res 2009 15 : 858 864.
22. Dimova S, Koleva M, Rangelova D, Stoythchev T. Effect of nifedipine, verapamil, diltiazem and trifluoperazine on acetaminophen toxicity in mice. Arch Toxicol 1995 70 : 112 118.
23. Liu J, Xu K, Wen G et al. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Bone 2008 42 : 950 959.
24. Bessard A, Fremin C, Ezan F, Fautrel A, Gailhouste L, Baffet G. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 2008 27 : 5315 5325.
25. Handerson T, Pawelek JM. Beta1,6-branched oligosaccharides and coarse vesicles: a common, pervasive phenotype in melanoma and other human cancers. Cancer Res 2003 63 : 5363 5369.
26. Jovanovic B, Krockel D, Linden D, Nilsson B, Egyhazi S, Hansson J. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol 2008 128 : 2696 2704.
27. Funasaka Y, Boulton T, Cobb M et al. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992 3 : 197 209.
28. Huang S, Luca M, Gutman M et al. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 1996 13 : 2339 2347.
29. Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006 155 : 1 8.
30. Samadder P, Richards C, Bittman R, Bhullar RP, Arthur G. The antitumor ether lipid 1-Q-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1. Anticancer Res 2003 23 : 2291 2295.
31. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 1999 59 : 2457 2463.
32. van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 2008 14 : 2061 2074.
33. Gao S, Liu GZ, Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 2004 59 : 214 225.
34. Hwang JT, Lee YK, Shin JI, Park OJ. Anti-inflammatory and anticarcinogenic effect of genistein alone or in combination with capsaicin in TPA-treated rat mammary glands or mammary cancer cell line. Ann NY Acad Sci 2009 1171 : 415 420.
35. Kwon DS, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Eur J Cell Biol 2006 85 : 1189 1199.